USV
Biosimilar developer, India. 3 development products across 3 molecules: pegfilgrastim, somatropin, teriparatide.
First approval in the Atlas: Aug 2012, USV (INN only), teriparatide (CDSCO)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved3
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Pegfilgrastim | USV pegfilgrastim | · | · | · | · | Sep 2019 | · |
| Somatropin | USV somatropin | · | · | · | · | Jun 2013 | · |
| Teriparatide | USV teriparatide | · | · | · | · | Aug 2012 | · |
Month shown is the first approval or registration of that product in that market.
Also holds or markets
Products developed by another company for which USV is the licence holder or applicant in one or more markets.
| Molecule | Brand | Market | Holder or applicant | Approved | Developer |
|---|---|---|---|---|---|
| Interferon alfa-2b | USV (INN only) | CDSCO | USV Ltd | Sep 2009 | Not stated in the CDSCO list |
Chronology
- CDSCOAug 2012USV (INN only), teriparatide
- CDSCOJun 2013USV (INN only), somatropin
- CDSCOSep 2019USV Private (INN only), pegfilgrastim
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.